3 documents found, page 1 of 1
Unmet needs of ambulatory cancer patients undergoing cancer treatments in a Por...
Simões, Filipa; Fortuna, Ana; Magalhães, Joana; Cerullo, Giovanni; Capelas, Manuel Luís; Pereira, José LuísBackground: Patients with cancer experience a variety of needs at every stage of their illness. Many of these needs can be addressed with palliative care. Cancer patients’ palliative needs should therefore be proactively identified and managed. This study aimed to identify the needs of oncology patients receiving out-patient cancer treatment at a Portuguese cancer center. Methods: A cross-sectional study was un...
Alectinib-induced anemia with acanthocytosis: To proceed or discontinue treatme...
Simões, Filipa; Sequeira, Telma; Rosa, Rita; Desterro, Joana; Almodovar, Maria TeresaALK gene rearrangements are important oncogenic driver alterations in non-small-cell lung cancer and a predictive factor. When present, it enables the use of tyrosine kinase inhibitors, such as Alectinib. This drug can lead to anemia and erythrocyte morphological changes. We present the case of a 72-year-old patient diagnosed with stage IV non-small cell lung cancer treated with Alectinib in the first line. The...
Retro tIming: A multicentric retrospective analysis of immunotherapy timing in ...
Gonçalves, Lisa; Goncalves, Duarte; Casanelles, Teresa Esteban; Guerra, Laura Pratas; Menezes, Maria B.; Branco, Vanessa Duarte; Luís, Joana AlvesImmune checkpoint inhibitors (ICI) targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are now the standard of care in the treatment of metastatic melanoma (mM). The interplay between cancer cells and tumor microenvironment cells (e.g. immune cells) impacts cancer cell survival, local invasion, and metastatic dissemination. Chrono-immunotherapy is an emergin...